Accelerated aging—where the body ages faster than chronological time—has long been suspected in people with HIV, even when the virus is well-controlled. This paper addresses a key question: does untreated HIV actually speed up molecular aging, and if so, does antiretroviral therapy (ART) reverse it? The researchers took a novel approach by building a 'proteomic aging clock' (PAC) using 416 different plasma proteins to predict chronological age in people on long-term ART, then tested whether this clock could detect premature aging in untreated individuals.
The study design was longitudinal and rigorous: 80 HIV-positive people provided blood samples at four timepoints spanning 17+ years—two samples while untreated (average 8 years apart) and two while on suppressive ART (average 10 years apart). This allowed direct before-and-after comparison within the same individuals, which is far more powerful than cross-sectional snapshots. The main finding was striking: the proteomic age during untreated infection was ~6 years higher than during suppressive ART (p=0.0001). Importantly, the trajectory analyses showed that PAC didn't just drop abruptly with ART; it gradually converged toward true chronological age with longer treatment duration, suggesting a genuine reversal rather than noise.
A significant strength is that the authors validated their findings against their own prior epigenetic aging work in the same cohort, showing consistency across independent molecular clocks. They also performed mediation analysis indicating that reversal of accelerated aging wasn't simply explained by immune recovery (CD4/CD8 counts), but rather reflects genuine changes in the broader proteome—pointing to mechanisms beyond immune reconstitution. The paper is transparent about using an independent longitudinal cohort to avoid overfitting, a common pitfall in aging-clock research.
However, there are important limitations. First, this is a preprint (not yet peer-reviewed), so findings await independent replication. Second, the sample size is modest (n=80 in the longitudinal analysis), and participants are predominantly from a wealthy, well-resourced Swiss cohort, limiting generalizability to resource-limited settings where HIV remains a burden. Third, the paper doesn't identify *which* proteins drive the aging signal or *why* they change—this is a 'black box' finding. Fourth, while the 6-year gap is clinically meaningful, proteomic age remained elevated even on ART, so the clock doesn't capture complete reversal to age-matched healthy controls (not provided). Finally, the study spans 17 years but the preprint date (2026) is in the future, which is unusual and raises questions about publication timeline.
This work fits into the broader longevity research framework by demonstrating that a major infectious disease (HIV) measurably accelerates biological aging at the molecular level, and that reversing infection—the goal of ART—genuinely reverses this acceleration. It strengthens the case for proteomic biomarkers as tools for tracking aging and disease burden, and highlights that controlling chronic viral infection may have benefits beyond traditional immune metrics. For HIV treatment strategy, this provides molecular evidence for the long-standing adage that 'undetectable = untransmittable' and extends it to 'undetectable = less biologically aged.'
In the context of aging research, the paper illustrates how omics technologies can detect subtle age-related changes missed by clinical parameters alone, though much work remains to translate these findings into actionable interventions.
0 Comments
Log in to join the discussion.